Bioprocessing Market Scope And Analysis

Report Code : TIPRE00039016
Category : Life Sciences

Status : Published
No. of Pages : 300

Buy Now

Bioprocessing Market Scope and Analysis by 2031

Buy Now

Bioprocessing Market Report Scope

Report Attribute	Details
Market size in 2023	US$ 25.35 Billion
Market Size by 2031	US$ 72.55 Billion
Global CAGR (2023 - 2031)	14.0%
Historical Data	2021-2022
Forecast period	2024-2031
Segments Covered	By Product Instruments Consumables and Accessories By Scale Of Operation Commercial Operations Clinical Operations By Process Downstream Bioprocess Upstream Bioprocess By Application Monoclonal Antibodies Vaccines Recombinant Protein Cell and Gene Therapy
Regions and Countries Covered	North America US Canada Mexico Europe France Germany UK Spain Italy Rest of Europe Asia Pacific China Japan India Australia South Korea Rest of Asia Pacific Middle East and Africa Saudi Arabia UAE South Africa Rest of Middle East and Africa and South and Central America Brazil Argentina Rest of South and Central America
Market leaders and key company profiles	Getinge AB Thermo Fisher Scientific Inc Sartorius AG Corning Inc Bio Rad Laboratories Inc Merck KGaA 3M Co Eppendorf SE Repligen Corp Entegris Inc

Recent Developments:

Companies operating in the bioprocessing market adopt strategic initiatives such as mergers and acquisitions, and partnerships. As per company press releases, a few recent market developments are listed below:

In February 2024, Cytiva and LevitasBio collaborated to deliver an innovative single-cell workflow for genomics researchers in academia and industry. This collaboration marked a significant milestone in improving how samples are prepared, enabling researchers to quickly perform tasks like breaking down tissues and purifying individual cell suspensions for single-cell analysis and other downstream applications. This is particularly important for advancing personalized medicine by providing insights into disease mechanisms and therapeutic targets, supporting oncology research, and accelerating scientific discovery.
In February 2024, Thermo Fisher Scientific Inc announced the expansion of its manufacturing facility in St Louis, which will support manufacturing biological therapies for rare diseases. Through the expansion, the company has doubled its biologics manufacturing capacity for complex biologic treatments, intending to enhance production from 2,000l to 5,000l for diseases, including cancer, autoimmune conditions, and rare disorders. The total area of the expanded site is 33,000ft² (3,065m²) and is equipped with four Thermo Scientific DynaDrive single-use bioreactors, each having a capacity of processing up to 5,000l.
In January 2024, Agilent Technologies Inc. announced an agreement with Incyte to bring together Agilent’s expertise and proven track record in developing companion diagnostics (CDx) to support the development and commercialization of Incyte’s hematology and oncology portfolio.
In November 2023, Cytiva introduced the innovative Cytiva Protein Select technology, designed to streamline and accelerate recombinant protein purification. The self-cleaving traceless tag and complementary affinity chromatography resin standardize purification for any protein, rendering it unnecessary to use specific affinity binding partners for each protein. Protein purification is integral to basic research, drug discovery, process development, and bioprocessing.